Sunday 18 October 2026
Export RLMD’s income statement to Excel — free account
Relmada Therapeutics, Inc.
RLMD Healthcare Biotechnology
In the quarter to June 2026, EPS grew 63.3% and free cash flow fell 50.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.10
0.10
−3.13%
Follow RLMD
Relmada Therapeutics, Inc. (RLMD) P/E ratio
Relmada Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 375× (April 2016) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 375×
Ten-year median
0.0×
Current reading's percentile
95
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TTRX Turn Therapeutics Inc. compare | n/m |
| ENTA Enanta Pharmaceuticals, Inc. compare | n/m |
| FENC Adherex Technologies Inc. compare | n/m |
| IRD Opus Genetics, Inc. compare | n/m |
| OBIO Orchestra BioMed Holdings, Inc. compare | n/m |
| AVIR Atea Pharmaceuticals, Inc. compare | n/m |
| RLMD Relmada Therapeutics, Inc. | n/m |
| CCCC C4 Therapeutics, Inc. compare | n/m |
| CYPH Cypherpunk Technologies Inc. compare | 4.4× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)